Latest News
- 5/25/2010
- AcelRx Announces Positive Phase 2 Results from a Study of ARX-02 Sufentanil NanoTabTM Breakthrough Pain Management System in Treating Cancer Breakthrough Pain (PDF, 18kB)
- 4/20/2010
- AcelRx Sufentanil NanoTab PCA System (ARX-01) Phase 2 Results Featured in Poster Presentations at the 35th Annual Meeting of the American Society of Regional Anesthesia and Pain to be held in Toronto on April 22-25th (PDF, 20kB)
- 4/06/2010
- AcelRx Pharmaceuticals Names Richard King Chief Executive Officer (PDF, 20kB)
- 10/30/2009
- AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management (PDF, 28kB)
- 10/22/2009
- AcelRx Announces Positive Results from a Phase 2 Study of ARX-03, a Sufentanil/Triazolam NanoTab for Procedural Sedation, Anxiolysis & Analgesia (PDF, 32kB)
- 10/15/2009
- AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting (PDF, 24kB)
- 10/14/2009
- AcelRx Pharmaceuticals Hires Nigel Ray as Vice President of Business Development (PDF, 20kB)
- 07/22/2009
- AcelRx Announces Perfect Performance of Handheld Component of ARX-01 Sufentanil NanoTab PCA System in a Phase 2 Study (PDF, 20kB)
- 06/29/2009
- AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain (PDF, 25kB)
- 05/05/2009
- AcelRx Initiates a Phase 2 Study to Evaluate Functionality of its ARX-01 Sufentanil NanoTab PCA System (PDF, 55kB)
- 04/22/2009
- AcelRx Announces Initiation of Phase 2 Cancer Breakthrough Pain Program (PDF, 20kB)
- 03/06/2009
- Mark Evashenk new Vice President, Clinical Operations press release (PDF, 24kB)
- 01/12/2009
- AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab™ (PDF, 107kB)
- 01/08/2009
- AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development (PDF, 17kB)
- 12/23/2008
- AcelRx Pharmaceuticals Scheduled to Present at the JP Morgan Healthcare Conference in San Francisco on January 15, 2009 (PDF, 24kB)
- 12/09/2008
- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study (PDF, 104kB)